Antiplatelet medications: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - "* " to "*") |
(add References section, add See Also section) |
||
| Line 22: | Line 22: | ||
**[[Thromboxane receptor antagonist]]s | **[[Thromboxane receptor antagonist]]s | ||
***[[Terutroban]] | ***[[Terutroban]] | ||
==See Also== | |||
*[[Antiplatelet agent reversal]] | |||
*[[Acute coronary syndrome]] | |||
*[[Stroke]] | |||
==References== | |||
<references/> | |||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
Latest revision as of 08:46, 22 March 2026
List
- Irreversible cyclooxygenase inhibitors
- Adenosine diphosphate (ADP) receptor inhibitors
- Clopidogrel (Plavix)
- Prasugrel (Effient)
- Ticagrelor (Brilinta)
- Ticlopidine (Ticlid)
- Phosphodiesterase inhibitors
- Cilostazol (Pletal)
- Protease-activated receptor-1 (PAR-1) antagonists
- Vorapaxar (Zontivity)
- Glycoprotein IIB/IIIA inhibitors (intravenous use only)
- Abciximab (ReoPro)
- Eptifibatide (Integrilin)
- Tirofiban (Aggrastat)
- Adenosine reuptake inhibitors
- Dipyridamole (Persantine)
- Thromboxane inhibitors